Browsing Tag

#LB1148

Palisade Bio Streamlines Operations and Identifies Capital Efficiencies to Focus All Resources on…

Jason Junior Sep 15, 2022

CARLSBAD, Calif., Sept. 15, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced that…

Health

Palisade Bio Announces First Patient Enrolled and Dosed in Pivotal Phase 3 Study Evaluating LB1148…

Jason Junior Aug 17, 2022

CARLSBAD, Calif., Aug. 17, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the first…

Health

Palisade Bio (Nasdaq: PALI) to Present at the Biocom Global Life Science Partnering Conference

Jason Junior Feb 18, 2022

CARLSBAD, Calif., Feb. 18, 2022 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI), a clinical stage biopharmaceutical company advancing therapies for acute and chronic gastrointestinal (GI) complications, will present at the Biocom…

Health

Palisade Bio Launches Clinical Steering Committee to Provide Clinical Oversight and Guide…

Jason Junior Jun 15, 2021

CARLSBAD, Calif., June 15, 2021 (GLOBE NEWSWIRE) -- Palisade Bio, Inc. (Nasdaq: PALI) a late-stage biopharma company advancing therapies for acute and chronic gastrointestinal (GI) complications, today announced the launch of its…